In February, 2017, Yung Shin's hepatitis B medication, Entecavir Tablet, was approved for marketing by the Japanese Ministry of Health, Labour and Welfare.

 Yung Shin Pharmaceutical reported another positive development. On February 15th, 2017, Yung Shin's vertically integrated active pharmaceutical ingredients and finished product, Entecavir Tablet, for chronic hepatitis B, successfully received approval from Japan's Ministry of Health, Labor and Welfare. Yung Shin is one of the first generic drug manufacturers to receive this license.

Hepatitis B is a global disease, primarily prevalent in Asia, Africa, Southern Europe, and Latin America. While some individuals with hepatitis B virus infection experience mild symptoms that suppress the virus, others develop long-term chronic infection. Entecavir tablets are an antiviral medication that, in adults with chronic HBV infection, is more effective than lamivudine in inhibiting viral replication and halting liver inflammation.

Yung Shin Pharmaceuitcal will officially launch Entercavir Tablet  in May this year after obtaining the Japanese drug reimbursement price, actively seeking the 1 billion yen market opportunity.